Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 36 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwitt R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31. [Ref.ID 100203]
3. Cita con resumen
Cederberg H, Stancáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109-17. [Ref.ID 99019]
4. Cita con resumen
McElduff A. Non-type 1, non-type 2 diabetes: what's in a name?. Australian Prescriber 2013;36:196-8. [Ref.ID 95647]
5. Cita con resumen
Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evidence Based Medicine 2012;17:171-6. [Ref.ID 93261]
6. Cita con resumen
Byrne CD, Wild SH. Increased risk of glucose intolerance and type 2 diabetes with statins. BMJ 2011;343:755-6. [Ref.ID 91743]
7. Cita con resumen
Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M, Collins P, Rosano GMC. Testosterone therapy in women with chronic heart failure. A pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56:1310-6. [Ref.ID 89238]
8.Tiene citas relacionadas
Roden M. Optimal insulin treatment in type 2 diabetes. N Engl J Med 2009;361:1801-3. [Ref.ID 87040]
9.Tiene citas relacionadas
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK, for the 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47. [Ref.ID 87037]
10. Cita con resumen
Gordon-Larsen P, Boone-Heinonen J, Sidney S, Sternfeld B, Jacobs Jr DR, Lewis CE. Active commuting and cardiovascular disease risk. The CARDIA study. Arch Intern Med 2009;169:1216-23. [Ref.ID 86335]
11. Cita con resumen
Wu RR, Zhao JP, Jin H, Shao P, Fang MS, He YQ, Chen JD, Li L-H. Lifestyle intervention and metformin for treatment of antipsychotic-induced wieght gain. A randomized controlled trial. JAMA 2008;299:185-93. [Ref.ID 82009]
12. Cita con resumen
Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: adverse effects of antiretroviral therapy. Lancet 2007;370:12-4. [Ref.ID 80487]
13. Cita con resumen
Garricho J, Lafita J, Moreno M. Rosiglitazona y pioglitazona. Evaluación crítica de los ensayos PROactive y DREAM. Boletín de Información Farmacoterapéutica de Navarra 2007;15:15-23. [Ref.ID 79792]
14.Tiene citas relacionadas Cita con resumen
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [Ref.ID 78151]
15.Tiene citas relacionadas Cita con resumen
Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same?. Lancet 2006;368:1218-9. [Ref.ID 78127]
16.Tiene citas relacionadas
Houston TK, Person SD, Pletcher MJ, Liu K, Iribarren C, Kiefe CI. Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study. BMJ 2006;332:1064-7. [Ref.ID 76940]
17.Tiene citas relacionadas
Panagiotakos DB. Passive smoking's role in diabetes. BMJ 2006;332:1044-5. [Ref.ID 76935]
18. Cita con resumen
Ho PM, Rumsfeld JS. Cardiac risk management in severe mental illness. Lancet 2006;367:1469-71. [Ref.ID 76862]
19.Tiene citas relacionadas
Tenkanen L, Mänttäri M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslpidemia. An 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006;166:743-8. [Ref.ID 76704]
20.Tiene citas relacionadas
Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression in insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006;166:737-41. [Ref.ID 76703]
Seleccionar todas
 
 1 a 20 de 36 siguiente >>